Clinical benefit #1
Among women presenting with pelvic mass, a combined use of HE4 and CA 125 using ROMA (Risk of Ovarian Malignancy Algorithm) can increase the sensitivity and specificity for assessing the risk of ovarian cancer - even stages I/II ovarian cancer – as compared to testing CA 125 alone.
- ROMA accurately identifies 94% of the patients with pelvic mass as having ovarian cancer6
- ROMA has a higher sensitivity than CA 125 alone: Among ten women with ovarian cancer, ROMA identifies one more patient than CA 125 alone (sensitivity: ROMA 90% vs. CA 125 79%)7
- ROMA has a higher specificity than CA 125 alone: Among ten women with benign gynecologic diseases, ROMA dismisses one more patient which CA125 alone would include as having ovarian cancer (Specificity: ROMA 93% vs. CA 125 86%)7
- ROMA has a higher sensitivity and specificity in detecting stages I/II ovarian cancer than CA 125 alone8
Clinical benefit #2
Determining HE4 and CA125 independently can improve ovarian cancer monitoring.
- Either HE4 or CA 125 levels can be elevated in patients during therapy monitoring and recurrence monitoring9-11
- At disease progression, some patients show an elevated HE4 level earlier than an increase in CA 125 level, and others show an elevated CA 125 level earlier than an increase in HE4 level. Therefore, HE4 and CA 125 together can effectively monitor therapy response9-11
- As patients with elevated CA 125 level at diagnosis can switch to elevated HE4 level at follow up, and vice versa, testing for both HE4 and CA 125 can identify patients with recurrent disease that CA 125 alone would miss11
Technical benefit
Efficiency and reliability for the laboratory
- Shows excellent precision across the entire measuring range for reliable results
- Uses a low sample volume (20 ul)
- Is fast with 18 minute assay time
- Is available for use in both serum and plasma
Consolidation of 17 tumor marker assays is available on one automated platform
